Isaacson I J
J Pain Symptom Manage. 1992 Aug;7(6):362-4. doi: 10.1016/0885-3924(92)90090-5.
This review considers a few of the controversies and most recent data pertaining to the clinical intraoperative use of the potent opioid sufentanil. Although sufentanil is used extensively as the opioid component of "balanced" anesthesia, opioids themselves are not total anesthetics. Sufentanil is effective in reducing the so-called stress responses that can occur with balanced anesthesia. Although no conclusive data have shown that such reduction in stress response improves anesthetic outcome, many clinicians continue to choose sufentanil for both convenience and improved hemodynamic control. Recent pharmacokinetic modeling suggests that sufentanil would be a good choice for balanced anesthesia. Additionally, initial postoperative analgesia appears to work better when sufentanil rather than fentanyl is used intraoperatively. Although cost considerations remain important, cost analysis would suggest that, on a per-patient basis, choice of intraoperative opioid has very little effect on total hospital costs.
本综述探讨了与强效阿片类药物舒芬太尼临床术中应用相关的一些争议及最新数据。尽管舒芬太尼作为“平衡”麻醉的阿片类成分被广泛使用,但阿片类药物本身并非完全麻醉剂。舒芬太尼可有效减轻平衡麻醉时可能出现的所谓应激反应。虽然尚无确凿数据表明应激反应的减轻能改善麻醉效果,但许多临床医生仍因方便及更好的血流动力学控制而继续选用舒芬太尼。近期的药代动力学模型表明,舒芬太尼是平衡麻醉的理想选择。此外,术中使用舒芬太尼而非芬太尼时,术后初始镇痛效果似乎更佳。尽管成本考量依然重要,但成本分析表明,就每位患者而言,术中阿片类药物的选择对医院总成本影响甚微。